Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2019-07-04 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
关于开立募集资金专项账户并授权经营层签订募集资金监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by the company regarding the opening of a special account for raised funds and authorization for management to sign a fund supervision agreement. It references regulatory approval for a non-public share issuance to raise funds and details the management of these funds. The document is short (712 characters) and is an announcement about fundraising procedures and compliance, not a financial report or detailed financial data. It fits the category of Capital/Financing Update (CAP) as it relates to fundraising activities and capital management.
2019-07-04 Chinese
关于转让浙江赛尚医药科技有限公司67%股权的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by a company regarding the progress of a share transfer transaction involving Zhejiang Saishang Pharmaceutical Technology Co., Ltd. It details the history of the share transfer agreement, payment delays, legal actions, court mediation, and current status of payments. The document is an update on a capital transaction and financing matter, specifically about the transfer of equity and related payments. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is not a regulatory filing about governance, management changes, or voting results. The content fits best under Capital/Financing Update (CAP) as it provides updates on the company's financing activities related to equity transfer.
2019-07-01 Chinese
关于转让浙江赛尚医药科技有限公司67%股权的进展公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding the progress of a share transfer transaction involving Zhejiang Saishang Pharmaceutical Technology Co., Ltd. It details the history of the share transfer agreement, payment delays, legal actions taken, court mediation, and current status of payments and enforcement rights. The document does not contain financial statements, audit results, or detailed financial performance data. It is not a report but an update on a specific transaction and related legal proceedings. This fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2019-06-28 Chinese
关于转让浙江赛尚医药科技有限公司67%股权的进展公告
Legal Proceedings Report Classification · 95% confidence The document is a public announcement by a company regarding the progress of the transfer of a 67% equity stake in another company. It details the history of the agreement, payment delays, legal actions taken, court mediation, and current status of payments. The document is an update on a specific transaction and legal proceedings related to it, rather than a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. It is not a notice of dividend, share issue, or capital change. It is not a regulatory certification or officer attestation. The content fits best with a Legal Proceedings Report as it discusses litigation, court mediation, and enforcement rights related to the equity transfer dispute.
2019-05-30 Chinese
2018年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement from the 2018 Annual General Meeting (AGM) of the company. It details the meeting date, attendance, voting results on various agenda items including the 2018 annual report, financial statements, profit distribution plan, and auditor appointment. The document focuses on the voting outcomes and procedural compliance of the AGM rather than presenting the full annual report or financial statements themselves. The length is about 3,076 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA).
2019-05-20 Chinese
2018年年度股东大会的法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2018 Annual General Meeting (AGM) of the company. It details the legality and procedures of the AGM, including the convening, attendance, voting procedures, and results of the shareholder meeting. The document does not contain the actual annual report or financial statements but rather confirms the validity and legality of the AGM process and its resolutions. The document length is 3697 characters, which is relatively short and focused on legal opinion about the AGM. This fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the AGM, including legal opinions related to the meeting. It is not a report publication announcement or a regulatory filing, as it contains substantive legal opinion content. Therefore, the correct classification is AGM Information (AGM-R).
2019-05-20 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.